s. flexneri 2a 2457t
Vaccineexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 21, 2022 (NCT04992520)
Timeline
Indications
Mechanism of action
- Shigella flexneriImmunity, active
Shigella flexneri immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07049159 | Phase 2 | Jun 30, 2025 | Eveliqure Biotechnologies GmbH |
| NCT04992520 | Phase 1 | Feb 21, 2022 | Department of Defense, Johns Hopkins University, PATH |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Department of Defense | Government | 1 | 0 | 1 | 2022 |
| Eveliqure Biotechnologies GmbH | For profit | 1 | 1 | 1 | 2025 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| PATH | Academic/Hospital | 1 | 1 | 1 | 2022 |
4 organizations
Page 1 / 1